Russia to begin COVID-19 vaccine trials on 40,000 people next week
Russia to begin COVID-19 vaccine trials on 40,000 people next week
"A "Each "I "Some "Sputnik (RDIF) (Reporting (Reuters) (WHO), (coronavirus) - 40,000 45 500 A Additional And Arab Arabia As At Brazil, Britain's But COVID-19 Chulanov, DIRECT Direct Dmitriev Dmitriev, Editing Emirates, Epidemiology FU Fund Gamaleya Gazeta.Ru He Health III INOCULATION INVESTMENT Ian In India, Institute Institute, Investment Ivanova; Jones, Kate Kelland; Kirill MOSCOW Macfie) Mass Microbiology, Ministry, Moscow Moscow's Nick October, Organization Phase Philippines. Polina President Putin RUSSIAN Reading Research Reuters/THE Russia Russia's Russia. Russian Saudi Soviet Sputnik TWO-SHOT The These This Thursday. Union, United University, V V" Vladimir WHO Western World a about academic according adenovirus-based adenovirus. administering against ahead aiming all allay alongside already among an and approval approved are around as assume at authorities backers background backing basis be been begin being billion body briefing. but by called capacity cases, centres check-ups. cited clinical collection commonly concerns conducted considered considering coronavirus countries country currently data details develop developed developers, did different differently," director disease diseases domestic doses doses." e early echoed ed effective eliciting enough ensuring experts far. first five following for foreign four from fully general get give given globally, groups, had hailed handout has have he head healthcare high-risk historic homage how however, human illness immune immunity, in including infection infectious information international internationally interview involve involved is it its itself jab, journal known lack large-scale last late-stage later launch leading least license light line long made manufacturing many mass may medical million month, months more name necessary next not not. of officials on onRussia one organisation, organisation. other others outside overseen participants participating partnerships, people per permit person photo place, possible, potential precursor previous process produce project protection protective proved provided public published range react received recombinant record records. registration registration. regular regulators, regulatory remains reporting requests research researchers response, results running safe safety said said, said. samples satellite saying sceptical, scientists seen several shape share should, showed shows significant six size small-scale small." so some specialist standards. start starts steps strong success. such supervised supporting symptoms. taken testing than that the theoretically, there think this three to told took track trial trial, trials trials, two two-shot unclear. until up upcoming use using usual vaccine vaccine, vaccine," vaccine. vaccine: vaccines vaccines, vector vectors very via virologist voluntary war warning was week week, were when which while who will with workers, world world's would year yet. ©
Russia to begin COVID-19 vaccine trials on 40,000 people next week
MOSCOW (Reuters) - Mass testing of Russia's first potential COVID-19 vaccine to get domestic regulatory approval will involve more than 40,000 people and will be overseen by a foreign research body when it starts next week, backers of the project said on Thursday.
© Reuters/THE RUSSIAN DIRECT INVESTMENT FU A handout photo shows samples of a vaccine against the coronavirus disease developed by the Gamaleya Research Institute of Epidemiology and Microbiology, in Moscow
These were the first details on the shape and size of the upcoming late-stage trial of the vaccine given by its developers, who are aiming to allay concerns among some scientists about the lack of data provided by Russia so far.
The vaccine, called "Sputnik V" in homage to the world's first satellite launch
ed by the Soviet Union, has been hailed as safe and effective by Russian authorities and scientists following two months of small-scale human trials, the results of which have not been made public yet.
But Western experts have been more sceptical, warning against its use until all internationally approved testing and regulatory steps have been seen to be taken and proved a success.
"A range of countries is running an information war against the Russian vaccine," Kirill Dmitriev, head of the Russian Direct Investment Fund (RDIF) that is backing the vaccine, told a briefing.
The vaccine data will be published in an academic journal later this month, he said.
Russia has received requests for up to a billion doses of the vaccine from around the world and has capacity to produce 500 million doses per year via manufacturing partnerships, he said.
A director at Moscow's Gamaleya Institute, which developed the vaccine, said 40,000 people would be involved in the mass testing at more than 45 medical centres around Russia.
The data is being provided to the World Health Organization (WHO), Dmitriev said, and to several countries that are considering participating in the late-stage trial, including the United Arab Emirates, India, Brazil, Saudi Arabia and the Philippines.
Sputnik V has already received approval from domestic regulators, leading President Vladimir Putin and other officials to name Russia the first country to license a COVID-19 vaccine.
The registration took place, however, ahead of the start of the large-scale trial, commonly known as a Phase III trial, considered by many as a necessary precursor to registration. At least four other potential COVID-19 vaccines are currently in Phase III trials globally, according to WHO records.
TWO-SHOT INOCULATION
But Russia's early registration of the vaccine will permit it to begin administering it to people in high-risk groups, such as healthcare workers, alongside the late-stage trial, from October, Dmitriev said.
He said the process would be conducted on a voluntary basis and participants would have regular medical check-ups.
The trial itself will be supervised by a foreign clinical research organisation, Dmitriev said, ensuring the data collection is fully in line with international standards. He did not give details of the research organisation.